MUC1 and idiopathic pulmonary fibrosis: Other examples of feasible IPF and LC-IPF treatment candidates include vantictumab, which interferes with Wnt signalling and has undergone Phase I trials for NSCLC (preclinical studies of Wnt pathway inhibition have also been performed in pulmonary fibrosis [258,259]), and Muc1-based therapeutic strategies.